New Micro Case Studies, have a look!

Posted by Fuld + Company on Oct 12, 2015 11:00:00 AM

Case studies are a curious animal. Everyone thinks they're important, but no one wants to write them, and, apart from the headlines, people don't really read them. They just want to know what was the challenge, what was done, how successful it was.

So at Fuld, we're introducing something new: the microinfographic case study. It's like the quick summary from a 3-5 page case study, with illustrations.

Read More

Topics: Competitive Intelligence, Brand Insights, Fuld + Company, Innovation, Pharma, Healthcare, Life Cycle Management, Life Sciences, Product Positioning, Competitive Strategy

The Tweet Heard ‘Round the Pharmaceutical World: A Perspective On Pharmaceutical Drug Pricing

Posted by Alexis Kuchins on Oct 5, 2015 3:22:18 PM

A week ago, presidential candidate Hillary Clinton tweeted her intentions, if elected, to try to curb the rising costs of pharmaceuticals. The plan would place a monthly cap on the out-of-pocket cost that chronic pain patients would have to pay for prescription medications, a greater emphasis on bringing biotechnology-style drugs to the market, and encourage increased use of generic and imported drugs.

Read More

Topics: Competitive Intelligence, Innovation, Market Analysis, New Market Entry, Pharma, Scenario Analysis, Healthcare, Industry Convergence, Life Sciences, Product Positioning, Competitive Strategy

Honest lessons from the C-Suite

Posted by Leonard Fuld on Sep 16, 2015 9:14:57 AM

How often do you get down and talk about honest mistakes and irreverent strategies with a CEO?

Over the past year I have had the privilege to interview over a half dozen former CEOs from companies the likes of JP Morgan, Corning, Harrahs/Caesar’s Casinos and Pearson. All companies with a global reach and encountering one challenge or another. I’ve collected these interviews in a special section of this website, C-Suite Candor.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Manufacturing/Industrial, Market Analysis, New Market Entry, Scenario Analysis, Technology/Telecomm, Industry Convergence, Merger and Acquisition, Product Positioning, Competitive Strategy

Sell-Offs and Mergers and Trades, Oh My!

Posted by Bruce Chin on Aug 18, 2015 11:44:41 AM

Current Trends in Big Pharma and What It Says About the Market

After unprecedented M&A activity in the last 20 years in Big Pharma, the trend of devolution isn’t just a topic that became popularised in Scotland. The pharmaceutical industry seems to be experiencing a similar trend. From the spin-off of AbbVie from Abbott in 2012 to Baxter’s specialised medicines spin-off, Baxalta, last month, the trend seems to be continuing. It continues with the swap of Novartis’s non-influenza vaccines business for the bulk of GSK’s oncology portfolio.

Read More

Topics: Competitive Intelligence, Market Analysis, Medical Devices, Pharma, Healthcare, Industry Convergence, Life Cycle Management, Life Sciences, Merger and Acquisition, Product Positioning, Competitive Strategy

Amazon Redefines the Grocery Store; the Industry Should Pay Attention

Posted by Robert Flynn on Aug 12, 2015 2:14:10 PM

As a youth, back before mobile phones and customer segmentation, I earned my allowance delivering orders to local customers, from the Mountain Heights corner store, a neighborhood grocery in New Haven, Connecticut. In those days, loyal customers – mostly elderly and all within a few blocks – would use the telephone to place an order for the usual array of soaps, cosmetics, and paper products. I’d earn a half dollar for my efforts. Mountain Heights had its corner of the city, while other grocers serviced their allotted section of the city. An idyllic setting.

Read More

Topics: Competitive Intelligence, Consumer Goods, Brand Insights, Innovation, Market Analysis, Scenario Analysis, Product Positioning, Competitive Strategy

Biosimilar Infliximab - What's All the Excitement About?

Posted by Adi Reske on Aug 11, 2015 11:05:24 AM

When in April this year the FDA accepted Celltrion’s filing for Remsima, the biosimilar Infliximab, patients and healthcare professionals in the United States were excited by the potential of a cheaper alternative to the expensive Remicade, an FDA approved tumor necrosis factor (TNF)-alpha inhibitor for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, Crohn's disease (CD), and ulcerative colitis (UC) . However, a couple of weeks before the anticipated advisory committee, the FDA postponed discussions for an unknown date, requesting more information from Celltrion. Meanwhile, the excitement died down.

Read More

Topics: Competitive Intelligence, Market Analysis, Medical Devices, Pharma, Healthcare, Life Cycle Management, Life Sciences, Product Positioning, Competitive Strategy

Knowing when to reject advice and why

Posted by Leonard Fuld on Jul 1, 2015 9:40:00 AM

An interview and discussion with Michel Darnaud, former President of Boston Scientific

During 2003-2004, the President of Boston Scientific Europe, Michel Darnaud, faced a critical decision: How to successfully roll out a new clot-resistant stent in the European marketplace against a gargantuan competitor with a product already in place. That competitor was Johnson & Johnson.

Read More

Topics: Competitive Intelligence, Consumer Goods, Product Roadmap, Brand Insights, Innovation, Market Analysis, Healthcare, Life Sciences, Product Positioning

Three Approaches to a Defined Strategy Roadmap

Posted by Alexis Kuchins on Jun 17, 2015 2:02:00 PM

A few weeks ago, I attended the Association for Strategic Planning (ASP) annual conference in Tysons Corner, VA. As this was my first entrée into the organization, I was excited to increase my strategy knowledge and skills, and take advantage of the various presentations. From the keynote speakers to the individual breakout sessions one thing was clear: without a defined strategy roadmap, one’s strategy is destined for a less then optimal outcome.

So how do you know if your strategy is on the path to success? Below are three paths to drive your business toward executing a highly impactful strategy.

Read More

Topics: Competitive Intelligence, Product Roadmap, Sales Force Effectiveness, Value Chain Analysis, War Games, Win/Loss/Bid Support, Events, Early Warning Monitoring, Innovation, Market Analysis, New Market Entry, Scenario Analysis, Life Cycle Management, Product Positioning

Not Your Dad's Private Label

Posted by Martha Culver on May 20, 2015 12:00:00 PM

Source: Repo Man

Quirky indie movie Repo Man is known, among other things, for featuring generic food displays with products labeled “Drink,” “Yellow Sliced Peaches,” and “Popcorn.” When the movie premiered in 1984, most people saw private label as a cheap, low-quality substitute for brand name products.

Read More

Topics: Consumer Goods, Brand Insights, Product Positioning

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.